GlassScriptPhysician profile
William Fabricius
NPI 1568698645
$11,320.85
in general payments reported to CMS, 2019-2025
49 companies · $1,771 in 2025
The $1,771 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,447 · 2021: $11.92 · 2022: $158 · 2023: $661 · 2024: $1,272 · 2025: $1,771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,151 · Education: $553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,151.04 |
| Education | $552.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $7,450.20 | 2019-2025 | Enhertu, Onglyza, Imfinzi |
| Astellas Pharma US INC | $590.23 | 2022-2025 | Xtandi, Padcev, Vyloy |
| Merck Sharp & Dohme LLC | $251.53 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Genentech USA, INC. | $183.25 | 2023-2025 | Venclexta, Polivy, Columvi |
| Celgene Corporation | $170.42 | 2023-2025 | Reblozyl, Pomalyst |
| Novartis Pharmaceuticals Corporation | $170.17 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $154.57 | 2024-2025 | Fruzaqla, Ninlaro |
| Incyte Corporation | $145.00 | 2023-2025 | Jakafi, Monjuvi, Zynyz |
| Pharmacyclics LLC, An Abbvie Company | $138.88 | 2022-2023 | Imbruvica, Epkinly |
| Daiichi Sankyo INC. | $134.87 | 2024-2025 | Enhertu, Injectafer |
| Glaxosmithkline, LLC. | $132.83 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Eisai INC. | $127.05 | 2024-2025 | |
| Seagen INC. | $119.65 | 2019 | |
| Janssen Biotech, INC. | $105.11 | 2024-2025 | Talvey, Tecvayli, Darzalex |
| Genzyme Corporation | $104.41 | 2023-2025 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Fabricius listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.